Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill ...

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold ...

The daily pill, called Foundayo, could make it easier for more people to lose weight.

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity ...

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form ...

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to ...

The fight between these two GLP-1 stocks has now entered round two. Novo Nordisk's Wegovy pill received approval in December, ...

A new review argues that gut dysbiosis is closely linked to metabolic dysfunction through intertwined effects on inflammation ...

A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen ...

Obesity is known to be a major risk factor that exacerbates metabolic disorders, such as type 2 diabetes. A key molecule ...